Price Alert

Theravance Biopharma Inc. (TBPH)

NASDAQ: TBPH · Real-Time Price · USD

14.41

-0.19 (-1.30%)

At close: Oct 01, 2025, 3:53 PM

Theravance Biopharma Statistics

Share Statistics

Theravance Biopharma has 50.36M shares outstanding. The number of shares has increased by 2.41% in one year.

Shares Outstanding	50.36M
Shares Change (YoY)	2.41%
Shares Change (QoQ)	0.72%
Owned by Institutions (%)	90.31%
Shares Floating	46.29M
Failed to Deliver (FTD) Shares	81,252
FTD / Avg. Volume	22.47%

Short Selling Information

The latest short interest is 5.13M, so 10.18% of the outstanding shares have been sold short.

Short Interest	5.13M
Short % of Shares Out	10.18%
Short % of Float	16.41%
Short Ratio (days to cover)	9.05

Valuation Ratios

The PE ratio is -8.15 and the forward PE ratio is 48.1. Theravance Biopharma's PEG ratio is -0.54.

PE Ratio	-8.15
Forward PE	48.1
PS Ratio	7.14
Forward PS	7.1
PB Ratio	2.62
P/FCF Ratio	-38.73
PEG Ratio	-0.54

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Theravance Biopharma.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 5.02, with a Debt / Equity ratio of 0.28.

Current Ratio	5.02
Quick Ratio	5.02
Debt / Equity	0.28
Debt / EBITDA	-1.3
Debt / FCF	-4.2
Interest Coverage	-18.44

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$663.72K
Profits Per Employee	$-581.63K
Employee Count	97
Asset Turnover	0.18
Inventory Turnover	n/a

Taxes

Income Tax	11.8M
Effective Tax Rate	-26.46%

Stock Price Statistics

The stock price has increased by 77.83% in the last 52 weeks. The beta is 0.05, so Theravance Biopharma's price volatility has been higher than the market average.

Beta	0.05
52-Week Price Change	77.83%
50-Day Moving Average	13
200-Day Moving Average	10.53
Relative Strength Index (RSI)	63.89
Average Volume (20 Days)	361,555

Income Statement

In the last 12 months, Theravance Biopharma had revenue of 64.38M and earned -56.42M in profits. Earnings per share was -1.15.

Revenue	64.38M
Gross Profit	64.38M
Operating Income	-46.95M
Net Income	-56.42M
EBITDA	-38.45M
EBIT	-42.07M
Earnings Per Share (EPS)	-1.15

Full Income Statement

Balance Sheet

The company has 37.8M in cash and 49.82M in debt, giving a net cash position of -12.02M.

Cash & Cash Equivalents	37.8M
Total Debt	49.82M
Net Cash	-12.02M
Retained Earnings	-965.52M
Total Assets	426.04M
Working Capital	311.66M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -11.54M and capital expenditures -332K, giving a free cash flow of -11.87M.

Operating Cash Flow	-11.54M
Capital Expenditures	-332K
Free Cash Flow	-11.87M
FCF Per Share	-0.24

Full Cash Flow Statement

Margins

Gross margin is 100%, with operating and profit margins of -72.92% and -87.63%.

Gross Margin	100%
Operating Margin	-72.92%
Pretax Margin	-69.3%
Profit Margin	-87.63%
EBITDA Margin	-59.73%
EBIT Margin	-72.92%
FCF Margin	-18.43%

Dividends & Yields

TBPH does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

The average price target for TBPH is $25, which is 71.2% higher than the current price. The consensus rating is "Buy".

Price Target	$25
Price Target Difference	71.2%
Analyst Consensus	Buy
Analyst Count	4

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	0.46
Piotroski F-Score	7